Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Paracetamol; Phenylephrine hydrochloride
Reckitt Benckiser Healthcare (UK) Ltd
Paracetamol; Phenylephrine hydrochloride
500mg ; 6.1mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04070100; GTIN: 5000158068377
OBJECT 1 LEMSIP MAX BLACKCURRANT FLAVOUR TABLETS Summary of Product Characteristics Updated 16-Jan-2014 | Reckitt Benckiser Healthcare (UK) Ltd • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Lemsip Max Blackcurrant Flavour Tablets 2. Qualitative and quantitative composition Each tablet contains 500 mg of paracetamol and 6.10 mg of phenylephrine hydrochloride. Excipients: Each tablet contains 40 mg of aspartame. For a full list of excipients, see Section 6.1. 3. Pharmaceutical form Tablet. A convex pale purple oval shaped tablet with blackcurrant odour. 4. Clinical particulars 4.1 Therapeutic indications For relief of symptoms of colds and influenza, including the relief of aches and pains, sore throat, headache, nasal congestion and lowering of temperature. 4.2 Posology and method of administration Adults (16 years and over): Two tablets every 4-6 hours to a maximum of four doses in any 24 hours. Do not exceed eight tablets in any 24 hours. Children 12-15 years: One tablet every 4 Read the complete document